NCT05201404Phase 3Listed as recruiting
Advanced liver cancer with Child-Pugh B7 cirrhosis: namodenoson, a medicine under study
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Minimum age: 18 years
Centres in: Cluj-Napoca · Craiova · Iași · and 2 more cities
See all centres (8)Hide the centre list
These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.
Central study contact
To find the team and exact institution in your chosen city, quote study NCT05201404. This contact may be in another country; ask which language you can use.
Source: study registry
We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.
Cluj-Napoca
Institutul Regional de Gastroenterologie si Hepatologie
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Craiova
Oncology Center "Sf. Nectarie" Medical Oncology
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)Oncolab SRL
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Iași
Euroclinic lasi
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)IRO Iasi-Clinica Oncologie Medicala
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Oradea
Spitalul Clinic Pelican Oradea Oncology Department
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Timișoara
Oncomed - Medical Oncology
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)Oncocenter Oncologie Clinica SRL
Contact for this study
Study Coordinator
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Who can take part
Advanced liver cancer with Child-Pugh B7 cirrhosis: namodenoson, a medicine under study
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
- Minimum age:
- 18 years
- Maximum age:
- Not specified in the record consulted
- Participant sex, as recorded in the registry:
- All sexes
This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.
Criteria published in the registry — English original
Inclusion Criteria: 1. Males and females at least 18 years of age. 2. Diagnosis of HCC: * For patients without cirrhosis at the time of diagnosis, histologic confirmation is required (archival tissue is acceptable). * For patients with underlying cirrhosis at the time of diagnosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Marrero 2018). 3. HCC is advanced (i.e., treatment-refractory or metastatic) and no standard therapies are expected to be curative. 4. HCC has progressed on at least 1, but no more than 2, prior systemic treatment regimens; prior locoregional therapy is allowed. 5. Barcelona Clinic Liver Cancer (BCLC) Stage B or C (Llovet 1999). 6. Prior HCC treatment was discontinued for at least 2 weeks prior to the Baseline Visit. 7. Measurable disease by RECIST v1.1 (Eisenhauer 2009). 8. ECOG PS of ≤ 1. 9. Cirrhosis classified as CPB7; if ascites is used as a scoring criterion, it must be classified as Grade ≥2 by the Clinical Practice Guidelines of the European Association for the Study of the Liver (EASL 2010). 10. The following laboratory values must be documented within ten days prior to the first dose of study drug: * Absolute neutrophil count (ANC) ≥ 1.5 × 109/L * Platelet count at least 75 × 10\^9/L * Creatinine clearance at least 50 mg/dL (estimated glomerular filtration rate by the Cockcroft-Gault or the Modification of Diet in Renal Disease methods) * AST and ALT ≤ 5 × the upper limit of normal (ULN) * Total bilirubin ≤ 3.0 mg/dL * Serum albumin ≥ 2.8 g/dL. 11. Life expectancy of ≥ 6 weeks. 12. For women of childbearing potential, negative serum pregnancy test result. 13. Provide written informed consent to participate. 14. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other trial-related procedures. Exclusion Criteria: 1. Receipt of \>2 prior systemic drug therapies for HCC. 2. Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids \> 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial. 3. Locoregional treatment within 4 weeks prior to the Baseline Visit. 4. Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit. 5. Use of any investigational agent within 4 weeks prior to the Baseline Visit. 6. Concomitant use of P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) inhibitors and/or substrates with a narrow therapeutic index unless the medication can be taken at least 3 hours before or after taking the investigational product (see Section 12.2). 7. Child-Pugh Class A, B8/9, or C cirrhosis. 8. Hepatic encephalopathy. 9. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion within 4 weeks prior to the Baseline Visit. 10. Uncontrolled or clinically unstable thyroid disease, per judgment of the Principal Investigator. 11. Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention. 12. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness. 13. Liver transplant. 14. Active malignancy other than HCC. 15. Uncontrolled arterial hypertension or congestive heart failure (New York Heart Association Classification 3 or 4). 16. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug. 17. History of, or ongoing, cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to \> 470 msec (patients with bundle branch block will not be excluded for QTc reasons). 18. Pregnant or lactating female. 19. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Investigator, are effective and adequate for the patient's circumstances while on study drug. 20. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug and for 3 months afterward. 21. Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with trial participation or study drug administration; may interfere with the informed consent process and/or with compliance with the requirements of the trial; or may interfere with the interpretation of trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.
What taking part involves
Participants are randomly assigned to the study groups.
These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.
Group 1 · Studied intervention
Namodenoson
Group 2 · Placebo comparison
Placebo
- Start of the whole study
- 15 March 2023
- Completion of the whole study
- October 2026 (estimated)
These are global study dates, not an individual's participation duration or an enrolment deadline.
Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.
Ask the study team before travelling:
- whether places are available at the chosen centre and how the first assessment is arranged
- how often you need to attend the centre and whether a hospital stay is necessary
- whether travel or accommodation costs are covered and under what conditions
- which documents you need to prepare and whether a family member or carer can accompany you
Original registry title
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Updated in the registry: 29 April 2025
Data consulted: 19 November 2026
See the official record ↗If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.
